Virtual Challenging Case Clinic: CAR T-Cell Therapy
Release Date: April 24, 2020
Expiration Date: April 24, 2021
This activity is for clinicians who treat patients with indolent and aggressive B-cell lymphomas: hematologists, medical oncologists, oncology nurses, nurse practitioners, oncology pharmacists, and other healthcare professionals.
After completing this activity, participants should be better able to:
- Evaluate best available evidence regarding treatment with CAR T-cell therapy
- Assess the implications of emerging clinical trial data regarding CAR T-cell therapy approaches
- Develop strategies to address complicated cases using CAR T-cell therapy
The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Nebraska Medical Center, Center for Continuing Education designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.
Method of Participation
There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.
Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.
Materials will be available online through April 24, 2021.
As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.
All presenters, planners, and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
All disclosed conflicts of interest have been resolved by independent content review.
This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the University of Nebraska Medical Center, Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.
All faculty and planning committee members have no conflicts to disclose with the exception of the following:
John P. Leonard, MD
Richard T. Silver Distinguished Professor of Hematology and Medical Oncology
Senior Associate Dean for Innovation and Initiatives
Executive Vice Chair, Joan and Sanford I. Weill Department of Medicine
Weill Cornell Medicine
New York, New York
Consulting Fees: ADC Therapeutics, AstraZeneca, Bayer, Bristol-Myers Squibb Company, Epizyme, a Kite Gilead Company, MEI Pharma, Miltenyi Biotec, Regeneron, Roche/Genentech, Sutro Biopharma
Julie Vose, MD, MBA
Neumann M. and Mildred E. Harris Professor
Chief, Division of Oncology/Hematology
University of Nebraska Medical Center
Consulting Fees: AbbVie, Acerta/AstraZeneca, Beigene, Epizyme, Janssen/Pharmacyclic, Karyopharm, Kite, a Gilead Company, Legend Pharmaceuticals, Nordic Nanovector, Novartis, Roche, Sandoz, Vaniam Group, Verastem
Grants/Research Support: Acerta Pharma, Amgen, AstraZeneca, Bristol Myers Squibb Company, Celgene Corporation, Incyte Corporation, Kite, a Gilead Company, Merck, Novartis, Seattle Genetics
Educational grant support provided by AstraZeneca, Bristol Myers Squibb, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc.
Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.